Co-Diagnostics, Inc. (CODX)
| Market Cap | 22.24M +91.7% |
| Revenue (ttm) | 718,166 -79.5% |
| Net Income | -48.50M |
| EPS | -29.82 |
| Shares Out | 3.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,139,842 |
| Open | 6.90 |
| Previous Close | 8.53 |
| Day's Range | 5.81 - 7.50 |
| 52-Week Range | 1.26 - 46.50 |
| Beta | 1.26 |
| Analysts | Hold |
| Price Target | 45.00 (+640.13%) |
| Earnings Date | May 14, 2026 |
About CODX
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In... [Read more]
Financial Performance
In 2025, Co-Diagnostics's revenue was $622,489, a decrease of -84.10% compared to the previous year's $3.92 million. Losses were -$46.90 million, 24.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for CODX stock is "Hold." The 12-month stock price target is $45.0, which is an increase of 640.13% from the latest price.
News
Co-Diagnostics files to sell 4.94M shares of common stock for holders
17:14 EDT Co-Diagnostics (CODX) files to sell 4.94M shares of common stock for holders
Co-Diagnostics Registration statement: Registration filing
Co-Diagnostics filed a registration statement on May 28, 2026, providing details about a securities offering with the SEC.
Co-Diagnostics trading halted, volatility trading pause
09:59 EDT Co-Diagnostics (CODX) trading halted, volatility trading pause
Co-Diagnostics and CoSara Diagnostics advance with ebola PCR development
Co-Diagnostics (CODX) announced that it has advanced the PCR assay development strategy for the Bundibugyo virus, or BDBV, currently causing an outbreak of Ebola disease in the Democratic Republic of…
Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara
Joint development strategy has been developed to address international deployment requirements if current outbreak continues or expands globally SALT LAKE CITY, May 26, 2026 /PRNewswire/ -- Co-Diagnos...
Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx", or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of mo...
Co-Diagnostics develops ebola assay strategy after recent global outbreak alert
Co-Diagnostics (CODX) has completed the assay development strategy for the Bundibugyo virus currently causing an outbreak of Ebola disease in the Democratic Republic of the Congo and Uganda. On May…
Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
Recent pathogens illustrate need for improved situational awareness capabilities, such as those provided by the Co-Dx PCR point-of-care platform Follows outbreak of Ebola and WHO emergency declaration...
Co-Diagnostics reports Q1 EPS ($4.06) vs. ($7.05) last year
Reports Q1 revenue $0.15M vs. $0.05M last year. Cash and cash equivalents totaled $8.2M as of March 31, 2026, vs. $11.9M as of December 31, 2025. “The progress we’ve made…
Co-Diagnostics Earnings Call Transcript: Q1 2026
Q1 2026 saw revenue growth but continued operating losses due to increased R&D and platform investments. Strategic progress includes clinical milestones, local manufacturing in India and Saudi Arabia, and automation initiatives, with additional capital likely needed for commercialization.
Co-Diagnostics Earnings release: Q1 2026
Co-Diagnostics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Co-Diagnostics Quarterly report: Q1 2026
Co-Diagnostics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Co-Diagnostics Reports First Quarter 2026 Financial Results
Advancing Global Commercialization Through CoSara Regulatory Progress and Regional Expansion Executing Clinical Strategy with Upper Respiratory Submission Preparation and TB Study Initiation Expanding...
Co-Diagnostics Slides: Investor presentation
Co-Diagnostics has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Co-Diagnostics files $150M mixed securities shelf
16:33 EDT Co-Diagnostics (CODX) files $150M mixed securities shelf
Co-Diagnostics Registration statement: Registration filing
Co-Diagnostics filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Co-Diagnostics’ joint venture with CoMira finalizes facility lease agreement
Co-Diagnostics (CODX) announced that its joint venture, CoMira Diagnostics, has finalized a lease agreement for its planned manufacturing facility in Sudair Industrial City in the Kingdom of Saudi Ara...
Co-Diagnostics Joint Venture CoMira Finalizes Lease Agreement for Manufacturing Facility in Saudi Arabia's Sudair Industrial City
Lease execution highlights transition from approval to development and advances localized manufacturing strategy in the Kingdom of Saudi Arabia in accordance with Vision 2030 SALT LAKE CITY, May 8, 20...
Co-Diagnostics Announces First Quarter 2026 Earnings Release Date and Webcast
SALT LAKE CITY, April 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C.
MTB test on Co-Dx PCR platform* to be presented at roundtable with Stop TB Partnership, U.S. Department of State, and global stakeholders SALT LAKE CITY, April 16, 2026 /PRNewswire/ -- Co-Diagnostics,...
Co-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, Germany
Company to engage with global customers and distributors while expanding international commercial relationships SALT LAKE CITY, April 14, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (t...
Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah
Trade mission itinerary of business, government, and industry briefings across Switzerland and Germany to include site visits to Roche Diagnostics, UBS, Zurich Innovation Park and more SALT LAKE CITY,...
Co-Diagnostics Earnings Call Transcript: Q4 2025
Revenue declined sharply year-over-year due to lower grant income, while operating expenses rose from a non-cash impairment. Strategic expansion in India and MENA, regulatory progress, and AI innovation position the business for future growth.
Co-Diagnostics Annual report: Q4 2025
Co-Diagnostics has published its Q4 2025 annual report on March 31, 2026.